$ cat ./records/gates-foundation-backs-novel-oral-polio-vaccine-type-2-nopv2-for--2020.txt
Gates Foundation Backs Novel Oral Polio Vaccine Type 2 (nOPV2) for Safer Polio Eradication
[RECORD.TXT] · cat --full
The Gates Foundation-supported Global Polio Eradication Initiative funded development and emergency use authorisation of the novel oral poliovirus vaccine type 2 (nOPV2), a genetically stabilised version of the existing bivalent OPV that reduces the risk of vaccine-derived poliovirus (VDPV) outbreaks. WHO granted nOPV2 emergency use listing in November 2020 — the fastest vaccine authorisation in WHO history at the time — enabling the GPEI to use a safer vaccine in response to type 2 VDPV outbreaks in Africa while protecting polio-free status.
Source: https://polioeradication.org/news-post/novel-oral-polio-vaccine-type-2-nopv2/
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Co-Sponsors WHO Defeating Meningitis by 2030 Roadmap Targeting 50% Case Reduction
Next →
Gates Foundation Funds Self-Amplifying RNA Vaccine Research at University of Washington for Dose-Sparing
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.